Works matching IS 17528054 AND DT 2023 AND VI 16 AND IP 7
Results: 17
A single ascending dose study of single‐stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1272, doi. 10.1111/cts.13531
- By:
- Publication type:
- Article
Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1258, doi. 10.1111/cts.13530
- By:
- Publication type:
- Article
Digital health technology derived measures: Biomarkers or clinical outcome assessments?
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1113, doi. 10.1111/cts.13529
- By:
- Publication type:
- Article
Safety assessment of a three‐dimensional‐printed autologous omentum patch: An application on the kidneys as a new treatment approach.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1121, doi. 10.1111/cts.13528
- By:
- Publication type:
- Article
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1243, doi. 10.1111/cts.13527
- By:
- Publication type:
- Article
Translation of the efficacy of antibody–drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1232, doi. 10.1111/cts.13526
- By:
- Publication type:
- Article
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1220, doi. 10.1111/cts.13525
- By:
- Publication type:
- Article
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1210, doi. 10.1111/cts.13524
- By:
- Publication type:
- Article
Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1197, doi. 10.1111/cts.13523
- By:
- Publication type:
- Article
In vivo tissue pharmacokinetics of ERBB2‐specific binding oligonucleotide‐based drugs by PET imaging.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1186, doi. 10.1111/cts.13522
- By:
- Publication type:
- Article
Continuous versus intermittent infusion of human antithrombin III concentrate in the immediate postoperative period after liver transplantation.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1177, doi. 10.1111/cts.13521
- By:
- Publication type:
- Article
Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality?
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1101, doi. 10.1111/cts.13520
- By:
- Publication type:
- Article
Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1127, doi. 10.1111/cts.13519
- By:
- Publication type:
- Article
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1163, doi. 10.1111/cts.13518
- By:
- Publication type:
- Article
Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1149, doi. 10.1111/cts.13517
- By:
- Publication type:
- Article
Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1134, doi. 10.1111/cts.13501
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1097, doi. 10.1111/cts.13326
- Publication type:
- Article